Article
The combination of multiple receptor tyrosine kinase inhibitor and mammalian target of rapamycin inhibitor overcomes erlotinib resistance in lung cancer cell lines through c-Met inhibition.
Molecular cancer research : MCR - 1 Aug 2010
Nakachi Ichiro, Naoki Katsuhiko, Soejima Kenzo, Kawada Ichiro, Watanabe Hideo, Yasuda Hiroyuki, Nakayama Sohei, Yoda Satoshi, Satomi Ryosuke, Ikemura Shinnosuke, Terai Hideki, Sato Takashi, Ishizaka Akitoshi
Abstract excerpt
Epidermal growth factor receptor tyrosine kinase inhibitors (EGFR-TKI) show antitumor activity in a subset of non-small cell lung cancer (NSCLC) patients. However, the initial tumor response is followed by recurrence. Several studies have suggested the importance of other receptor tyrosine kinase...
Read the complete abstract on PubMedTopics
Share this publication in a Topic to start or enrich a Post.